Al Sandrock, Voyager CEO
Voyager nabs $25M cash as Novartis runs with two AAV capsids for neuro gene therapy
After spending a year looking at Voyager’s next-gen AAV capsids, Novartis has picked two of them to be the delivery vector for its gene therapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
